Citadel Advisors’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-94,256
| Closed | -$940K | – | 13428 |
|
|
2025
Q2 | $940K | Sell |
94,256
-1,085,466
| -92% | -$8.74M | ﹤0.01% | 7244 |
|
|
2025
Q1 | $7.04M | Sell |
1,179,722
-252,540
| -18% | -$1.85M | ﹤0.01% | 3358 |
|
|
2024
Q4 | $11M | Buy |
1,432,262
+196,003
| +16% | +$1.68M | ﹤0.01% | 2863 |
|
|
2024
Q3 | $12.6M | Buy |
1,236,259
+538,927
| +77% | +$8.22M | ﹤0.01% | 2582 |
|
|
2024
Q2 | $10.3M | Sell |
697,332
-471,332
| -40% | -$6.75M | ﹤0.01% | 2728 |
|
|
2024
Q1 | $15.9M | Buy |
1,168,664
+38,876
| +3% | +$424K | ﹤0.01% | 2327 |
|
|
2023
Q4 | $12.4M | Buy |
1,129,788
+122,216
| +12% | +$1.21M | ﹤0.01% | 2577 |
|
|
2023
Q3 | $11M | Sell |
1,007,572
-187,697
| -16% | -$2.4M | ﹤0.01% | 2572 |
|
|
2023
Q2 | $15.8M | Sell |
1,195,269
-248,231
| -17% | -$3.54M | ﹤0.01% | 2122 |
|
|
2023
Q1 | $19.6M | Buy |
1,443,500
+88,073
| +6% | +$1.58M | ﹤0.01% | 1934 |
|
|
2022
Q4 | $26.5M | Buy |
1,355,427
+33,544
| +3% | +$655K | 0.01% | 1670 |
|
|
2022
Q3 | $25.2M | Buy |
1,321,883
+608,171
| +85% | +$14M | 0.01% | 1649 |
|
|
2022
Q2 | $14.7M | Buy |
713,712
+192,241
| +37% | +$4.56M | ﹤0.01% | 2197 |
|
|
2022
Q1 | $16.8M | Sell |
521,471
-477,470
| -48% | -$17.3M | ﹤0.01% | 2205 |
|
|
2021
Q4 | $46.5M | Buy |
998,941
+23,523
| +2% | +$783K | 0.01% | 1225 |
|
|
2021
Q3 | $26.3M | Sell |
975,418
-18,978
| -2% | -$496K | 0.01% | 1689 |
|
|
2021
Q2 | $25.5M | Buy |
994,396
+483,398
| +95% | +$11.5M | 0.01% | 1794 |
|
|
2021
Q1 | $17.5M | Sell |
510,998
-286,316
| -36% | -$10.3M | ﹤0.01% | 2142 |
|
|
2020
Q4 | $27M | Sell |
797,314
-100,975
| -11% | -$2.67M | 0.01% | 1504 |
|
|
2020
Q3 | $22.2M | Buy |
+898,289
| New | +$24.2M | 0.01% | 1488 |
|
Other funds holding ITOS
Citadel Advisors's ITOS Position: Q3 2025 in Review
Citadel Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 94,256 shares — an estimated $940K sold.
Citadel Advisors first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $46.5M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Citadel Advisors reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 94,256 iTeos Therapeutics shares in Q3 2025, an estimated $940K.
- Citadel Advisors first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Citadel Advisors's iTeos Therapeutics position peaked at $46.5M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.